20:17 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Generon's benegrastim meets in Phase III for CIN

Generon (Shanghai) Corp. Ltd. (Shanghai, China) reported data from a Phase III trial in about 122 women with stage II-IV breast cancer patients receiving myelotoxic chemotherapy with docetaxel and doxorubicin showing that a 20 mg...
07:00 , May 14, 2012 |  BC Week In Review  |  Clinical News

F-627: Phase II started

Generon began an open-label, international Phase II trial to compare F-627 vs. Neulasta pegfilgrastim in about 200 breast cancer patients receiving myelotoxic chemotherapy. Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neulasta. Generon (Shanghai)...